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Formation of the initial enzyme of the alternative pathway and generation of the 
metastable binding site of C3b may be intimately linked to the presence ofa thioester 
bond in the C3 molecule. The metastable binding site of C3b was described in  1966 
(1), but its chemical basis remained obscure until recently. The site effects the firm 
attachment of the activated metastable C3b to a wide variety of biological particles. 
It  thereby enables  C3b  to  fulfill  its  functions  in  the  assembly  of both  activation 
pathways on the surface of target cells and in opsonization reactions (2). 
Recently, two observations helped to clarify the chemical nature of the metastable 
binding site. It was shown that bound C3bis probably linked to targets via a covalent 
bond in which a carbonyl group of C3b forms an ester with a hydroxyl group of the 
target  surface  (3,  4).  Secondly, C3b  was  shown  to contain  a  sulfhydryl group  not 
detectable in  native C3  (5).  Both the sulfhydryl and  the  reactive carbonyl groups 
were  found to be located  in  the  d-domain  of the  alpha-chain,  which  is  known  to 
contain the binding site of C3b. It may be postulated, therefore, that the two groups 
form an internal thioester in native C3 (6, 7). 
That C3 loses its hemolytic activity upon treatment with amines such as hydrazine 
is  known  (8).  In view of the described recent findings, the amine sensitivity of C3 
assumes  a  new  significance.  In  the  present  study,  native  C3  was  treated  with 
methylamine because this amine is available in radiolabeled form. Concomitant with 
loss  of C3  hemolytic activity,  1 mol  of methylamine became bound  and  1 mol of 
sulfhydryl became exposed per mol of C3. 
It  is  the  purpose  of this  paper  to  report  that  methylamine-treated C3  behaves 
functionally like C3b with respect to (a) Factor B and/~IH binding, (b) susceptibility 
to cleavage by C3b inactivator, and (c) the ability to form a fluid-phase C3 convertase 
in presence of Faiztors  B and D, and Mg  ++. The possibility is raised that C3b-like C3 
may be produced under physiological conditions by the reaction of C3 with water. 
We wish to propose that C3b-like C3 arises by nonenzymatic spontaneous thioester- 
bond hydrolysis of C3 and thereby effects formation of a steady-state concentration 
of the initial C3 convertase of the alternative pathway of complement activation. 
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Materials and Methods 
Purified Components and Reagents.  Highly purified C3 (9), Factor B (10),  Factor D  (11), fllH 
(12), C3b inactivator (12),  activated properdin (13, 14), cobra venom factor (GoF)  1 (15), and 
partially purified nephritic factor (16)  were prepared as described. C3b was generated from 
purified C3  (3  mg/ml)  either by  5-min  incubation with  2  /zg/ml  trypsin  (TPCK  treated; 
Worthington Biochemical Corp., Freehold, N.J.) followed by 4 #g/ml soybean trypsin inhibitor 
(Sigma Chemical Co., St. Louis, Mo.) or by a  10-min incubation at 37°G with 30/~g/ml Factor 
B and  2 #g/ml  Factor D  in the presence of 5 mM MgGI2. C3 hemolytically inactivated by 
incorporation of methylamine [G3(GHaNHz)] was prepared by 30-min incubation at 37°G with 
0.2 M  CHsNH2 at pH 8. Excess methylamine was removed by dialysis. 
[14C]methylamine hydrochloride (50.1  mGi/mmol)  and  [1-1*G]iodoacetamide (24.9  mCi/ 
mmol)  were  obtained  from  New  England  Nuclear,  Boston,  Mass.  as solutions  in  ethanol. 
Unlabeled methylamine hydrochloride was obtained from Sigma Chemical Co. Radioiodina- 
tion of proteins was performed according to the method of Fraker and Speck (17) using Iodogen 
(Pierce Chemical Co., Rockford, Ill.). Sheep erythrocytes (Ks) that bore specifically attached 
C3b (EsC3b) were prepared as described previously (18). 
Buffers.  The  buffers were as follows: isotonic veronal-buffered saline, pH  7.4  (VB);  VB 
containing 0.1%  gelatin and  1.2 mM MgCi2 (Mg-GVB); VB containing 0.1%  gelatin and  10 
mM EDTA (GVBE); and one-half-ionic strength VB containing 0.1% gelatin, 0.15 mM CaCI2, 
0.5 mM MgCI2, and 2.5% glucose (DGVB). 
Preparation of Anti-C3a-Sepharose.  Antiserum was raised to purified human C3a (19) in a goat. 
The  protein  precipitated from  this  antiserum  with  40%  saturated  ammonium  sulfate  was 
coupled to CNBr-activated Sepharose. Affinity chromatography-purified anti-C3a antibodies 
were isolated from the antisera by passage over C3a lacking the C-terminal arganine residue 
(iC3a)-Sepharose. 
Incorporation of [t4C]Methylamine into C3d Released  from Zymosan.  Zymosan was incubated for 
2 h  at 37°C with normal human serum that contained a  1:20 dilution of 0.1  M  MgCI2 that 
contained  0.1  M  EGTA  (MgEGTA).  After a  thorough  washing,  the  zymosan bearing the 
inactivated form of C3b generated upon cleavage by C3b inactivator (iC3b) was treated with 
5 #g/ml trypsin for 20 min at 37°C to convert iC3b to C3d. The Gashed particles were then 
incubated for 6 h at 37°C with 4 M  guanidine, 2 mM [14C]methylamine (10 #Ci), and 0.1  M 
sodium phosphate buffer, pH 8. Unbound label was removed by passage over Sephadex G-25 
in 6 M guanidine. The labeled protein fraction was dialyzed against 10% acetic acid, lyophilized, 
and subjected to polyacrylamide gel electrophoresis in sodium dodecyl sulfate (SDS). 
Assays.  C3  assays were  performed by the effective molecule titration method  described 
earlier (20).  The activity of the fluid-phase properdin-stabilized C3 eonvertases formed using 
C3b or C3(CHsNH2) was determined by the rate of C3 consumption at 37°C. Binding assays 
for  the  measurement  of the  interaction  between  xzsI-fllH and  EsC3b  were  performed  as 
previously described (18).  Competition between cell-bound C3b and fluid-phase C3, C3b, or 
C3(CHsNH2)  for xzsI-factor  B  was measured in DGVB containing 4  mM  MgCI2. The assay 
mixtures contained 5 X  10  7 EsC3b  (bearing 80,000 C3b/eeil), 2 #g t25I-faetor B  (10 nCi/#g), 
and various amounts of C3, C3b, or C3(CHsNH2)  in a  total vol of 100 #1. The samples were 
incubated  10 min at 21°C and centrifuged in a  Beckman microfuge (Beckman Instruments, 
Inc., Fullerton, Calif.). The amount  of radiolabeled Factor B  bound was determined by its 
depletion from the supernate. Quantitation of functional C3b bound to Es was performed by 
incubation of 1.5 X  10  v cells with 300 ng Factor B and  10 ng Factor D in 20 #1 Mg-GVB for 3 
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buffered saline that contained 0.1% gelatin and 10 mM EDTA; DGVB, half-ionic strength veronal-buffered 
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min at 37°C to allow cell-bound C3-convertase formation. Lysis was determined  after addition 
of 1 ml of guinea pig serum (2% in GVBE) and incubation for 10 min at 37°C. 
C3 Consumption in Serum.  Activation of the alternative  pathway in serum by the addition of 
C3b or C3(CH3NH2) was measured  as C3 consumption after 20 rain  at  37°C. The reaction 
mixtures contained 25 #1 normal human serum, 5 #l 0.1 M MgEGTA, and various amounts of 
C3, C3b, C3(CHaNH2) (1.9 mg/ml), or buffer to yield a final volume of 110 #1. C3 activity was 
assayed as described above. Samples that recieved additions  of native C3 were compared with 
controls  that contained EDTA; the amount of C3 consumed  was calculated  as if all of the 
consumption  represented consumption of the serum-derived C3. 
Electrophoresis and Scintillation Counting.  Analysis of intermediates  formed during proteolytic 
digestion of [t4C]methylamine-labeled C3 was performed  by SDS polyacrylamide  gel electro- 
phoresis using the method of Laemmli (21). The gel slices were solubilized with an NCS tissue 
solubilizer (Amersham Corp., Arlington  Heights,  Ill.) and analyzed with a Beckman LS-8000 
liquid  scintillaition  counter (Beckman  Instruments,  Inc.)  using  the toluene-based  scintillant 
Scinti Verse (Fisher Scientific Co., Pittsburgh,  Pa.) that contained 5% acetic acid and 8% water. 
Results 
Stoichiomet~y of the Reaction of Methylamine  with C3.  Incubation of native human C3 
with  radiolabeled  methylamine  led  to  inactivation  of C3  hemolytic  activity  and 
concomitant incorporation of methylamine into the protein (Fig.  1). C3 at a concen- 
tration  of 2.7  mg/ml  was  incubated  at  37°C  and  pH  8.0  with  12.6  mM  [14C]- 
methylamine  (15.9  mCi/nmol),  20  mM  sodium  phosphate,  and  0.15  M  sodium 
chloride. Samples were removed at time intervals and diluted  15-fold in cold GVBE. 
Part  of the diluted  sample was used  for titration  of C3 hemolytic activity and  the 
remainder passed over Sephadex G-25 to remove unbound methylamine. The rate of 
loss  of hemolytic activity was  identical  to  the  rate  of methylamine  incorporation. 
Uptake  ceased  at  0.87  mol of methylamine/mol of C3.  Similar  treatment  of C3b 
resulted in uptake of only 0.03 mol of methylamine/mol of C3b. 
Localization of Methylamine  in the d-Domain of the a-Chain.  To determine the location 
of the amine in C3(CHsNH2), the protein was enzymatically converted to C3b and 
iC3b, and to C3c and C3d.  C3(CHsNH2) and its fragments were analyzed by SDS 
polyacrylamide gel electrophoresis under reducing conditions. As shown in Fig. 2, the 
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Fzc,  1.  Stoichiometry of the incorporation of radiolabeled methylamine by C3 (C)) and correlation 
of incorporation with the loss of hemolytic function (0). M.  K.  PANGBURN  AND  H. J.  MULLER-EBERHARD 
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F=o.  2.  Localization of the methylamine-reactive site to the C3d portion of C3.  Polyacrylamlde 
gel electrophoresis in the presence of SDS and dlthiothreitol of C3(CHsNHz)  and its breakdown 
products. [14C]methylamine-labeled C3 (100/~g in 100/x|) was converted to C3b by mild trypsini- 
zation  (1  #g,  5  rain, 37°C  followed by  2 /~g soybean trypsin  inhibitor),  iC3b  was produced by 
treatment  of C3b  with 5  /~g/ml  C3bINA and  50 /~g/ml fllH  for 20  min  at  37°C.  Subsequent 
addition of 3 pg trypsin generated the C3c and C3d fragments. Only the C3d fragment contained 
radiolabel. The arrows indicate the positions of the C3 a-chain (Mr  110,000)  and C3 fl-chain (Mr 
75,000). 
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TABLE  I 
Quantitation of Free Sulfhydryl Groups in C3, C3b, and C3(CH3NH2  ) 
Mol iodoacetamide incorporated/mol C3 
In buffer  In 0.45 M  guanidine 
C3  0.04  0.22 
C3b  0.74  0.91 
C3(CHaNH2)  0.31  1.22 
radiolabel was found in the a-chain of C3, the a'-chain of C3b (a-chain of C3b minus 
C3a), the a'-67,000 piece of iC3b, and C3d (Mr =  31,000). Methylamine released C3d 
bound to zymosan particles and in the process was incorporated into the protein. The 
release reaction was performed in presence of 4 M  guanidine hydrochloride. 
Appearance of an Iodoacetamide Reactive Group after Methylamine Treatment of C3.  Table 
I shows the results of reacting C3(CHaNH2), C3, and C3b with [z4C]iodoacetamide. 
The  protein  preparations  were  incubated  at  pH  7.2  and  37°C  for 30  min  with  a 
sevenfold molar excess of iodoacetamide. Native C3 incorporated less than 0.04 tool 
of the sulfhydryl reagent/mol protein. C3b and C3(CHaNH2) bound 0.74 and 0.31 
mol/mol, respectively. In the presence of 0.45 M guanidine, binding of iodoacetamide 
to C3b and C3(CHaNH2)  increased to 0.91  and  1.22  tool, respectively. More than 
80% of the label was found in the a-chain of C3(CH3NH2), in the a'-67,000 piece of 
iC3b, and in C3d, both derived from the modified protein. 
Reactivity of C3 with Nucleophiles Other than Methylamine. The sensitivity of C3  to a 1106  PUTATIVE THIOESTER BOND IN HUMAN C3 
series of nucleophilic compounds  bearing  increasingly bulky alkyl-side chains  was 
examined. Fig. 3 shows that C3 was inactivated by methylamine 73 times faster than 
by ethylamine, and  750 times  faster than  by isopropylamine.  No  inactivation was 
observed with t-butylamine. The small differences in ionization constants (pKa) and 
nucleophilicity of these compounds do not account for the rate differences observed. 
Therefore, a sterically restricted site is postulated for the amine-sensitive group in C3. 
To examine  the  probable  physiological  mechanism  of modified C3  production, 
several nucleophilic compounds found in plasma were tested. Water at pH  7.3 and 
37°C  effected a  loss of C3  hemolytic activity of 0.5%/h.  Loss of activity was  much 
accelerated in the presence of low concentrations of chaotropic agents.  For instance, 
0.33 M  KSCN caused 50% inactivation in 8 min, and 0.75 M  guanidine effected 50% 
inactivation in  12 min. Ammonia at 0.05 M  or ethanolamine at 0.2 M  caused 50% 
inactivation  in  1 h.  The  results  suggest  that  at  normal  plasma  concentrations  of 
ammonia (12/~M), ethanolamine (1.7/LM), and methylamine (0.1/~M), these nucleo- 
philes cause inactivation of only 0.005% C3/h. It appears that direct hydrolysis of C3 
by water probably plays a greater role in generating C3b-like C3 in plasma than do 
amines. 
Presence of the C3a Domain on C3(  CHsNH2  ) and Relative Resistance of the Modified Protein 
to  Cleavage by  C3 Convertases.  The possibility was  considered that  in  the  course of 
methylamine modification of C3, the C3a domain was removed from the molecule. 
This possibility could be ruled out  because C3(CHsNH~)  was  bound  by anti-C3a- 
Sepharose and this binding could be inhibited by purified C3a. Binding could also be 
prevented by prior treatment of C3(CH3NH2) with trypsin, which dissociates C3a by 
poteolytic cleavage. C3 convertases cleaved C3(CH3NH.!) less efficiently than C3. At 
low enzyme:substrate ratios, cleavage of C3(CH3NH2) was negligible. When a sixfold 
molar excess of CoF-dependent  C3  convertase was  employed, definite cleavage of 
C3(CH3NH2) occurred, but the reaction did not go to completion in 30 rain at 37°C. 
Similar results were obtained with the classical and alternative C3 convertases. 
Interaction of C3(CH~H2) with Factor B and ~IH.  The binding of Factor B to ceU- 
bound  C3b  can  be inhibited  by fluid-phase C3b.  Fig.  4  shows  that  C3(CHsNH2), 
unlike native C3, can also inhibit Factor B binding to celi-bound C3b, indicating that 
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FEc.  3.  Inactivation of C3 hemolytic activity at pH 8 by 0.025 M  methylamine (gg) and 0.2 M 
ethylamine (O), isoprop|ylamine (&), or t-buty]amine (0). Control incubations in 20 mM sodium 
phosphate buffer alone showed no inactivation. M.  K.  PANGBURN  AND  H. J.  MI]LLER-EBERHARD  1107 
1004 
== 
c 
•  ~  80- 
•  60- 
00 
40- 
~  20- 
et 
1'o  l's  fo 
/~g of Competitor Added 
Fro.  4.  Acquisition of affinity for Factor B by methylamine treatment of C3. Competition by fluid- 
phase C3  (A), C3(CHaNH2)  (O), and C3b  (0)  with the binding of 12SI-Factor  B to EsC3b. The 
assays contained 5  X  107 EsC3b and  2/*g I25I-Factor  B  in a  final volume of 100/d  DGVB that 
contained 4 mM MgCI2. Binding was determined after 10 min at 21°C by measuring the decrease 
of radioactivity in the fluid phase after removal of the cells. 
TABLE II 
Inhibition of Factor B and fl l H Binding to Ez SC3b by Fluid-Phase 
C3(CHaNH2) or C3b 
Competitor 
Amount of competitor required for 50% 
inhibition of component binding* 
,  B binding  fllH binding 
#g 
C3  494  205 
C3b  5  19 
C3(CHaNH2)  9  6 
* Factor B binding to EsC3b in the presence of fluid-phase competitors was 
measured as described in Materials and Methods. fllH binding to EsC3b 
was measured as previously described (18), except for the presence of fluid- 
phase competitors in the reaction mixture. 
C3(CHaNH2)  behaves  in  this  respect  like  C3b.  Similar  results  were  obtained  with 
fllH  (Table  II),  indicating  the  existence  of fllH-  and  Factor  B-binding  sites  on 
C3(CH3NH2). 
Cleavage of C3(CHaHN2)  by  C3b Inactivator and fllH.  Fig.  5  shows  the  results  of 
exposing C3(CHzNH2)  to C3b inactivator  (C3bINA) and fllH.  SDS polyacrylamide 
gel  electrophoresis  analysis  under  reducing  conditions  showed  that  the  a-chain  of 
C3(CH3NH2) was cleaved directly without prior conversion of the protein to C3b. In 
comparison with  similarly  treated  C3b, which yielded  the known a'-67,000 and  a'- 
40,000  fragments  and  the  75,000  mol  wt  fl-chain,  C3(CHaNH2)  yielded  the  same 
fragments,  except  that  the  larger  of the  two  a-chain  pieces  was  ~10,000  dalton 
heavier.  This fragment,  therefore,  migrated  together with  the beta-chain  and,  in all 
probability, contains the C3a domain. 
Activation  of the  Alternative  Pathway in  Serum by  C3(CHaNH2).  To  assess  whether a'-67,000 
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Fic.  5.  Cleavage  of C3(CH3NH3) by C3blNA and fll H. (Left) Polyacrylamide  gel electrophoresis 
in the presence of SDS and dithiothreitol of l~I -C3b after a brief incubation with C3blNA and 
fllH. The two a'-chain cleavage products, a'-67,000 and a'-40,O00, are indicated. (Right) Similar 
treatment of ~2~I-C3(CHaNH2)  showed only the a'-40,O00  and a proportional increase  in radioactivity 
in the  75,000 M, fl-chain peak. The a-76,000 chain appears to be composed of a'-67,000 and 
covalently linked C3a. 
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Fic. 6.  C3  consumption in  human serum upon  addition  of C3(CHaNH~). C3  consumption 
occurred via alternative pathway activation in MgEGTA containing serum after the addition of 
C3b (0),  C3(CHaNHz) (O), or native C3  (A). Control, (El). Experimental details are given in 
Materials and Methods. 
altered  C3b-like C3  can  form  a  C3  convertase in serum  and,  therefore,  might  be 
responsible for the initial C3b deposition that triggers alternative pathway activation, 
high concentrations of C3(CH3NH2)  were added to normal human serum in which 
the  classical complement pathway  had  been  blocked.  Fig.  6  shows  that  like C3b, 
C3(CHaNH2) was capable of initiating C3 consumption via the alternative pathway. 
Similar results  were  obtained  with  C3  treated  with  l  M  KSCN  or  subjected  to 
repeated freeze thawing. The latter two treatments presumably resulted in hydrolysis 
of the thioester bond. 
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tase  can  be  formed  with  C3(CHaNH~)  as  with  C3b,  5  gg  of C3(CHsNH2)  was 
incubated with 8/~g Factor B, 2 #g activated properdin, and 0.5 #g Factor D  in the 
presence of 2 mM Mg  ++ for 3 rain at 37°C. Continued formation of convertase was 
blocked by addition of EDTA before the substrate, native C3, was added. C3b was 
used for comparison. Fig. 7 shows that C3(CHaNH2), like C3b, was capable of forming 
a C3 convertase, as evidenced by consumption of C3. 
Deposition of EsC3b  by  Fluid-Phase C3  Convertase that  Contains C3(CH3NH~).  To 
determine whether the fluid-phase C3 convertase formed by C3(CHsNH2) was capable 
of catalyzing C3b  deposition  onto cells  and,  thus,  sustaining  alternative  pathway 
initiation,  the  following experiment was  performed. Reaction  mixtures were made 
containing 1.5 ×  107 sheep erythrocytes, various amounts of native C3, and constant 
amounts of the preformed C3 convertase prepared with 0.5 gg of C3(CHsNH2). The 
total reaction volume was  100 gl. A parallel set of samples contained C3b instead of 
C3(CHaNH2). The reaction was allowed to proceed for  15 min at  37°C.  The cells 
were washed and then assayed for the presence of functional C3b on their surface as 
described in Materials and Methods. No C3b deposition was observed in the absence 
of C3(CHaNH2)  or C3b.  As Fig.  8  demonstrates, in  depositing C3b  from the fluid 
phase onto the cells, the C3(CHaNH2)  containing C3 convertase was as efficient as 
the C3b containing C3 convertase. 
Discussion 
It is known that the ability of the alternative pathway to proceed on the surface of 
activating particles depends entirely on the initial deposition of C3b molecules (22, 
23).  Deposition requires enzymatic cleavage of C3 in the fluid phase and generation 
of metastable C3b that  is capable of binding to biological particles. Therefore, the 
obvious question has been: What is the nature of the initial C3 convertase? If the C3- 
derived subunit of this enzyme were C3b, an additional protease would have to be 
postulated as a  constituent of the alternative pathway. It has been established that 
the initial C3 convertase of the alternative pathway is dependent on C3, Factors B 
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Fzo.  7.  Demonstration that C3(CHaNHa)  (O, right panel) forms a  functional C3 convertase with 
Factors B  and D  and properdin. For comparison, the C3 convertase formed using C3b is shown 
(O, left panel). C3 consumption by the preformed, C3b containing convertase was not inhibited by 
the addition of antibodies to C3a (0, left panel), whereas the C3(CHaNH2)  containing convertase 
was completely inhibited by antibodies to C3a (0, right panel), demonstrating that only the latter 
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Ftc. 8.  Deposition  of C3b on sheep erythrocytes (Es) by a fluid-phase C3 convertase containing 
C3(CHsNH2). Fluid-phase  conversion of various amounts of native C3 to C3b in the presence of Es 
was catalyzed by properdin(P)-stabilized  C3 convertases  that contained either C3(CHaNH2) or C3b. 
Deposited C3b was assayed  as described in Materials and Methods. O, C3b, Bb, P; &, C3(CHaNH2), 
Bb, P. 
and  D, and Mg  ++, but not on properdin or other factors (22-25).  Lachmann et al. 
(26-28) envisioned, as the initiating event, a spontaneous tick-over of C3 that resulted 
in continuous low level C3b formation in vitro and in vivo without evoking the need 
for exogenous activation. Fearon and Austen  (29)  suggested that native C3 together 
with  Factors  B  and  D,  and  possibly properdin,  can  form  a  convertase capable of 
generating  initial  C3b.  It  was concluded  in  this  laboratory  that  native C3,  rather 
than C3b,  is  the critical subunit  of the  initial  123 convertase because experimental 
evidence indicated that the enzyme was a fluid-phase enzyme and that no extraneous 
proteases were involved in its formation (25, 30). The ability of native uneleaved C3 
to initiate formation of the initial enzyme was attributed to the probable occurrence 
of reversible conformers of C3 that express affinity for Factor B  (2). 
The observations reported in this paper strongly suggest that a  heretofore unrec- 
ognized form of C3, distinct from native C3, constitutes the C3-derived subunit of the 
initial  enzyme.  Incubation  of native  C3  with  low  molecular  weight  nucleophilic 
reagents  results  in  loss  of  C3  hemolytic  activity  (1,  8,  15,  31).  In  the  case  of 
methylamine (6, 7, 32), a covalent incorporation of the amine has been demonstrated. 
C3(CH~NHz) has been found in this study to be functionally C3b-like, although the 
123a domain of the molecule remained covalently attached. The observations are as 
follows: (a) Fluid-phase C3(CHaNH2) was shown to compete with cell-bound C3b for 
binding  of Factor  B  and  fllH.  (b)  C3(CHsNH2)  was  cleaved  by  C3bINA  in  the 
presence of flirt. Of the two a-chain products, one was shown to be larger than the 
analogous a'-67,000 fragment of C3b (12)  by approximately the molecular weight of 
C3a.  (c)  Addition  of C3(CHsNH2)  to  human  serum  caused  C3  consumption  to  a 
similar extent as the addition ofC3b. (d) C3(CHsNH2) formed a C3 convertase in the 
presence  of isolated  Factors  B  and  D  and  Mg  ++,  much  like  C3b.  Passage  over a 
Sepharose  anti-C3a  column  removed  the  convertase-forming  material  from 
C3(CHzNH2),  but  not  from  123b. The  preformed  C3  convertase  prepared  with 
C3(12HsNH2) was inhibited by purified anti-C3a, whereas the C3b containing enzyme M.  K.  PANGBURN  AND  H.  J.  MOLLER-EBERHARD  1111 
was unaffected. These experiments demonstrated conclusively that the C3(CHaNH2)- 
induced C3 convertase contained a C3a-bearing form of C3. 
It is known that a low-rate spontaneous consumption of C3 occurs in nonactivated 
plasma. It is probable that a spontaneously arising, altered form of C3 is responsible. 
However, a role of low molecular weight amines in the formation of the altered C3 is 
doubtful because of their low plasma concentration. The most effective nucleophile in 
plasma is probably water because its concentration is 55 M. Direct hydrolysis of the 
putative thioester bond in C3 may provide, under physiological conditions, a steady 
source  for C3b-like C3.  The  known effects of chaotropic reagents such  as  KBr or 
KSCN on C3 hemolytic activity and physiochemical properties (33) supports the view 
that C3 hemolytically inactivated by water hydrolysis of the thioester bond [C3(H20)] 
may be formed in a manner analogous to C3(CH3NH2). Chaotropic reagents perturb 
the secondary and  tertiary structure of proteins  (34) and, in  the case of C3,  may 
facilitate the reaction of water with the putative thioester. 
The hypothesis that C3 contains an intramolecular thioester has evolved from the 
following evidence: (a) Inactivation of the plasma protease inhibitor a2-macroglobulin 
by  methylamine  results  from  the  covalent  incorporation  of  the  reagent  as  the 
methylamide of a glutamic acid residue (32).  (b) A covalent reaction of methylamine 
also occurs with C3.  (c) Simultaneously, a  free sulfhydryl group appears in C3.  (d) 
Compared with C3b, it was difficult to react the sulfhydryl group in C3(CH3NH2) 
with iodoacetamide without the aid of denaturing agents, suggesting proximity of the 
methylamine-reactive  site  to  the  sulfhydryl group.  (e)  A  peptide  sequence  that 
contains  the  methylamine-reactive glutamyl  residue  of a2-macroglobulin  has  the 
structure: Gly-Cys-Gly-Glu-Glu*-Asn-Met- (32),  where the asterisk (*)  indicates the 
residue  that  contained  the  methylamine.  (f)  The  methylamine-substituted  and 
carboxymethylated peptide of iodoacetamide-treated C3(CH3NH2) exhibited an iden- 
tical seven amino acid residue sequence (B. F. Tack. Personal communication). Thus, 
the iodoacetamide-reactive cysteinyl residue and the methylamine-reactive glutamyl 
residue are separated only by two amino acid residues. 
Fig. 9 shows the chemical reactions at the activated carbonyl site of C3 that the 
present hypothesis predicts. A thioester is shown for the reasons summarized above, 
but the same reactions would occur whether an ester (4), amide, or carbonyl group 
were present in a  reactive form. The sensitivity of C3 to nucleophilic attack results 
from  the scission of the  reactive bond  and  incorporation of the  nucleophile.  The 
methylamine product is shown. Water hydrolysis of the thioester would yield -OH 
in place of the methylamide. As demonstrated in this paper, nucleophilically altered 
C3 can form an alternative pathway C3 convertase, which proteolytically converts C3 
to metastable C3b by cleavage of peptide bond 77 of the a-chain and dissociation of 
C3a (35). The reactive site of metastable C3b, according to the present hypothesis, is 
a highly reactive form of the thioester capable of undergoing transesterification with 
-OH  groups on carbohydrate-bearing surfaces. Failing to encounter an appropriate 
receptive surface, metastable C3b reacts with water, forming fluid-phase C3b. These 
reactions explain the formation of the initial C3 convertase and the mechanism of 
C3b deposition required by current theories of alternative pathway activation. 
Summary 
The reaction of [14C]methylamine with native human C3 led to the stoichiometric 
incorporation of methylamine, loss of hemolytic activity, and the concomitant expo- 1112  PUTATIVE THIOESTER  BOND IN HUMAN C3 
proteolytic enzymes  O = C 
(-C3a) 
NATIVE C3  METASTABLE C3b 
,  (,  O = C--NHCH3  O = C--OH 
SH 
receptive  O~~__  C_O 
surface  R 
(+ROH)  "  ~  SH 
SURFACE-BOUND C3b 
Q,~  O=C-OH 
FLUID-PHASE "C3b-like"  C3  FLUID-PHASE  C3b 
C3(CH3NH2)  C3(H20) 
FIG. 9.  Proposed chemical reactions at the activated carbonyl site of C3. Current evidence suggests 
that an  intramolecular thioester bond  in the a-chain of C3  becomes the  reactive group  of the 
metastable binding site of proteolytically produced C3b. C3 altered by nucleophilic attack or water 
hydrolysis of the thioester becomes functionally C3b-like without proteolytic release of C3a. 
sure of a sulfhydryl group that could be labeled with [14C]iodoacetamide. Both labeled 
sites were located in the C3d portion of the a-chain, which is known to contain the 
metastable binding site of C3b. 
The methylamine-modified C3  [C3(CH3NH2)] was shown to exhibit many of the 
functional  properties of C3b,  although  the  C3a  portion  of the  molecule  remained 
covalently attached.  C3(CH3NH2)  bound  Factor B  and/31H,  and could be cleaved 
by C3b  inactivator  in  the  presence of ~IH. C3(CHzNH2)  added  to  human  serum 
caused activation of the alternative pathway and consumption of C3. In presence of 
Factors B and D  and Mg  ÷+, C3(CH3NH2)  formed a  C3 convertase. The convertase- 
forming material  could  be removed  from solution  by anti-C3a  Sepharose  and  the 
preformed convertase was completely inhibited  by purified  antibody  to C3a.  This 
antibody did not affect the function of the C3 convertase that contained C3b. Similar 
functional  properties  were  exhibited  by  C3  exposed  for  short  periods  of time  to 
relatively low  concentrations  of chaotropic  reagents,  such  as  KSCN  or  guanidine. 
These results suggest that the initial C3 convertase of the alternative pathway may be 
formed from native C3, without proteolysis, by the attack of a variety of nucleophiles 
including  water. The C3 convertase formed from this altered C3 then generates by 
proteolytic cleavage the initial metastable C3b that is capable of attaching to receptive 
surfaces. Conversion of C3 to C3b exposes one sulfhydryl residue as does modification 
of C3 with methylamine. When the C3d portion of C3b bound to zymosan particles 
via  the  metastable  binding  site  was  treated  with  radiolabeled  methylamine,  the 
fragment was  released  from the  particles  in  radiolabeled  form.  These  findings  are 
consistent  with  the  concept  that  native  C3  contains  an  active  carbonyl  group, 
probably  in  the  form  of a  thioester,  which  can  either  react  with  water  to  form 
functionally C3b-like C3 or, upon enzymatic conversion of C3 to C3b, allows C3b to 
form an ester bond with hydroxyl groups on the target surface. M.  K.  PANGBURN  AND H. J.  MULLER-EBERHARD  1113 
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